95% of rare diseases have zero approved treatments. Rarefind uses AI to discover which existing approved drugs could work for rare diseases -- evidence-scored, literature-backed, free for researchers.
Enter any rare disease. Rarefind covers 6,000+ conditions from the Orphanet and OpenTargets databases.
Our AI scores existing approved drugs against the disease across 4 evidence dimensions: genetic, structural, pathway, and literature.
Every prediction includes a detailed evidence report with data sources, references, and confidence scoring. No black boxes.
Every drug-disease pair is scored across four independent evidence dimensions.
Do the drug's targets overlap with genes associated with this disease? Source: OpenTargets, OMIM, DisGeNET.
Does the drug bind to proteins involved in the disease pathway? Source: ChEMBL binding data (15M+ bioactivity data points).
Does the drug affect biological pathways disrupted in this disease? Source: pathway analysis from known drug and disease mechanisms.
Has anyone published research linking this drug to this disease? Source: PubMed abstracts, ClinicalTrials.gov.
Rarefind Therapeutics is building the AI platform to discover treatments for every rare disease. We believe that the 300 million people living with rare diseases deserve the same research attention as common diseases. Our platform uses knowledge graphs and multi-target scoring to identify which existing approved drugs could be repurposed for rare disease indications -- at a fraction of the cost and time of traditional drug development.
Our long-term vision: an autonomous AI system that designs therapeutic strategies for any rare disease, making the impossible economics of rare disease drug development viable through computational intelligence.